Pfizer (NYSE:PFE) Posts Earnings Results, Beats Expectations By $0.13 EPS

Key Points

• Pfizer beat third-quarter expectations: Adjusted EPS was $0.87 versus the $0.74 consensus, while revenue reached $16.58 billion against estimates of $15.85 billion. Revenue was essentially flat year over year.
• Management raised its full-year 2026 revenue and adjusted EPS outlook, citing cost reductions, commercial momentum and strong demand for Eliquis. New and acquired products grew 32% during the quarter, helping offset weaker COVID-19 product sales.
• Pfizer declared a quarterly dividend of $0.43 per share, equivalent to a 5.6% annualized yield. Analysts remain broadly neutral, with an average “Hold” rating and a consensus price target of $28.65.

Pfizer (NYSE:PFE - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13, Zacks reports. The business had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business's quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the business earned $0.87 EPS.

Pfizer Stock Up 0.8%

Shares of Pfizer stock opened at $30.90 on Tuesday. The company has a market cap of $176.14 billion, a P/E ratio of 40.45, a PEG ratio of 2.00 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer has a one year low of $23.62 and a one year high of $31.06. The firm has a fifty day moving average of $28.60 and a two-hundred day moving average of $26.82.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's payout ratio is currently 226.32%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PFE shares. Weiss Ratings upgraded shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Cantor Fitzgerald upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, October 8th. Scotiabank increased their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 6th. HSBC raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, September 10th. Finally, Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Five analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $28.65.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Quarterly results exceeded expectations. Pfizer reported third-quarter adjusted earnings of $0.87 per share, above analyst estimates ranging from $0.72 to $0.74. Revenue of $16.58 billion also surpassed the approximately $15.85 billion consensus, although it was essentially flat year over year. Pfizer Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Pfizer raised its full-year 2026 revenue and adjusted EPS outlook. Management cited strong year-to-date performance, cost reductions and commercial momentum. Demand for Eliquis, the company’s blood thinner, was specifically identified as a key driver. Pfizer Raises 2026 Forecast on Strong Demand for Eliquis
• Positive Sentiment: Growth is broadening beyond COVID products. Newly launched and acquired products reportedly grew 32% in the quarter, helping offset weaker vaccine and treatment sales and supporting the view that Pfizer’s pipeline and portfolio can generate post-pandemic growth. Pfizer Raises Forecast on Momentum With New Products
• Neutral Sentiment: Cecile Guegan was appointed permanent chief financial officer. The company veteran had served as interim CFO since August and brings familiarity with Pfizer’s finances and strategy, reducing transition risk but representing continuity rather than a major strategic change. Pfizer Appoints Cecile Guegan as Chief Financial Officer
• Negative Sentiment: Underlying revenue remains pressured. Third-quarter sales were down slightly from the prior year, and declining COVID-19 vaccine and treatment revenue continues to weigh on comparisons. Additionally, after a recent rally toward a 52-week high, some investors may question whether the earnings and guidance improvements are already reflected in the stock. Pfizer Just Gained 12 Percent in a Month

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.